Interestingly, mice treated with murine-specific FSHR-targeted CAR T cell boosted endogenous pre-existing anti-tumor immunity in an immune-competent mouse model [113], further validating results seen by Alizadeh et al. in the context of IL-13Rα2-targeted CAR T treatment in patients with GBM [101]. Here, IL13RA2 is linked to neoplasm.